Palivizumab
- Generic Name
- Palivizumab
- Brand Names
- Synagis
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 188039-54-5
- Unique Ingredient Identifier
- DQ448MW7KS
- Background
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
- Indication
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
- Associated Conditions
- Severe Respiratory Syncytial Virus Infection
- Associated Therapies
- -
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT04938830
- Locations
- 🇺🇸
DHR Health Institute for Research and Development ( Site 0029), Edinburg, Texas, United States
🇺🇸NYU Langone Hospital - Long Island-Pediatrics ( Site 0028), Mineola, New York, United States
🇺🇸Miller Children's & Women's Hospital Long Beach ( Site 0001), Long Beach, California, United States
Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- mAbxience Research S.L.
- Target Recruit Count
- 56
- Registration Number
- NCT04540627
- Locations
- 🇬🇧
hVIVO Services Limited, London, United Kingdom
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 925
- Registration Number
- NCT03959488
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 50
- Registration Number
- NCT02968173
"Palivizumab Therapy for RSV-bronchiolitis"
- Conditions
- Interventions
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Hamad Medical Corporation
- Target Recruit Count
- 420
- Registration Number
- NCT02442427
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 28
- Registration Number
- NCT01466062
- Locations
- 🇯🇵
Site Reference ID/Investigator# 56847, Hyogo, Japan
🇯🇵Site Reference ID/Investigator# 56843, Yokohama, Japan
🇯🇵Site Reference ID/Investigator# 56842, Tokyo, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.